SavedAdd your journal

Journals / The European Research Journal / 2020 / Cilt: 6 - Sayı: 6

Evaluation of tear function tests and corneal thickness in patients with meibomian gland dysfunction

Kuddusi TEBERİK
İlter İRİTAŞ
Pages
609–614
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: The Schirmer test and CCT measurements are not significantly different in patients with MGD compared to healthy control subjects.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: To investigate whether central corneal thickness (CCT) and tear function test differ from healthy controls in the ones suffering meibomian gland dysfunction (MGD).
📊
Key Findings & Data:Methods: This prospective study was carried out with 99 individuals in total (50 patients MGD, 49 healthy individuals).
💡
Conclusion & Impact:Conclusions: The Schirmer test and CCT measurements are not significantly different in patients with MGD compared to healthy control subjects.
🔬Design:Survey & Empirical Study
📍Scope:Comprehensive Sample
⚙️Variables:Meibomian gland dysfunction · Schirmer-1 test · tear break-up time

Abstract

Objectives: To investigate whether central corneal thickness (CCT) and tear function test differ from healthy controls in the ones suffering meibomian gland dysfunction (MGD). Methods: This prospective study was carried out with 99 individuals in total (50 patients MGD, 49 healthy individuals). Schirmer-1, tear break-up time (TBUT), the Ocular Surface Disease Index (OSDI) questionnaire and CCT measurmentwas administered to all patients.Results: The average Schirmer 1 measurements were 16.6 ± 3.3 mm for right eyes, 16.4 ± 3.6 mm for left eyes in the MGD group and 17.1 ± 3.7 mm for right eyes, 17.0 ± 4.4 mm for left eyes in the control group. The mean TBUT values were 10.1 ± 3.6 seconds for right eyes, 10.2 ± 3.4 seconds for left eyes in the MGD group and 14.7±3.7 seconds for right eyes, 15.8 ± 4.1 seconds for left eyes in the control group (p = 0.001). The mean OSDI score values were 40.3 ± 23.7 in the MGD group and 19.4 ± 8.7 in the control group (p = 0.001). The average CCT in the MGD group was 539.4 ± 30.0 µm and 539.7 ± 33.0 µm (right and left, respectively). The average CCT in the control group was 551.6 ± 32.8 µm and 550.7 ± 32.2 µm (right and left, respectively). The mean CCT measurements in the MGD group were not statistically significant compared to the healthy control group (p = 0.059, and p = 0.097, right and left, respectively). Conclusions: The Schirmer test and CCT measurements are not significantly different in patients with MGD compared to healthy control subjects.

🔖

Cite This Article

TEBERİK, K., İRİTAŞ, İ. (2020). Evaluation of tear function tests and corneal thickness in patients with meibomian gland dysfunction. The European Research Journal, Cilt: 6 - Sayı: 6, 609–614. https://ajindex.com/articles/360997

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Greiner JV, Glonek T, Korb DR, Whalen AC, Hebert E, Hearn SL, et al. Volume of the human and rabbit meibomian gland system. In: Lacrimal Gland, Tear Film, and Dry Eye Syndromes 2. Springer, Boston: MA; 1998: pp. 339-43
  2. Mishima S, Maurice DM. The oily layer of the tear film and evaporation from the corneal surface. Exp Eye Res 1961;1:39-45
  3. Nichols KK, Foulks GN, Bron AJ, Glasgow BJ, Dogru M, Tsubota K, et al. The international workshop on meibomian gland dysfunction: executive summary. Invest Ophthalmol Vis Sci 2011;52:1922-9
  4. Bron AJ, Tiffany JM. The contribution of meibomian disease to dry eye. Ocul Surf 2004;2:149-65
  5. Lemp MA, Nichols KK. Blepharitis in the United States, a survey-based perspective on prevalence and treatment. Ocul Surf 2009;7:1-14
  6. Blackie CA, Korb DR, Knop E, Bedi R, Knop N, Holland EJ. Nonobvious obstructive meibomian gland dysfunction. Cornea 2010;29:1333-45
  7. Nicolaides N, Kaitaranta JK, Rawdah TN, Macy JI, Boswell FM 3rd, Smith RE. Meibomian gland studies: comparison of steer and human lipids. Invest Ophthalmol Vis Sci 1981;20:522-36
  8. Bron AJ, Benjamin L, Snibson GR. Meibomian gland disease. Classification and grading of lid changes. Eye (Lond) 1991;5:395-411
  9. Driver PJ, Lemp MA. Meibomian gland dysfunction. Surv Ophthalmol 1996;40: 343-67
  10. Yeh S, Song XJ, Farley W, Li DQ, Stern ME, Pflugfelder SC. Apoptosis of ocular surface cells in experimentally induced dry eye. Invest Ophthalmol Vis Sci 2003;44:124-9
  11. Pole JJ, Batzer JK. Central corneal thickness of patients with dry eyes. J Am Optom Assoc 1985;56:220-1
  12. Doughty MJ, Zaman ML. Human corneal thickness and its impact on intraocular pressure measures: a review and meta-analysis approach. Surv Ophthalmol 2000;44:367-408. 13. deSanctis U, Missolungi A, Mutani B, Richiardi L, Grignolo FM. Reproducibility and repeatability of central corneal thickness measurement in keratoconus using the rotating Scheimpflug camera and ultrasound pachymetry. Am J Ophthalmol 2007;144:712-8
  13. Karadayi K, Ciftci F, Akin T, Bilge AH. Increase in central corneal thickness in dry and normal eyes with application of artificial tears: a new diagnostic and follow-up criterion for dry eye. Ophthalmic Physiol Opt 2005;25:485-91
  14. Mathers WD. Ocular evaporation in meibomian gland dysfunction and dry eye. Ophthalmology 1993;100:347-51
  15. Craig JP, Tomlinson A. Importance of the lipid layer in human tear film stability and evaporation. Optom Vis Sci 1997;74:8-13. 17.